{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T16:00:21Z","timestamp":1775318421409,"version":"3.50.1"},"reference-count":36,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objective: Patients with severe asthma (SA) and non-cystic fibrosis bronchiectasis (BE) without microbiological colonization represent a unique and understudied population. Type 2-targeted biologic therapies have emerged as a promising treatment for these patients. However, predictive factors for achieving clinical remission remain unclear. This study aims to identify the predictive factors for achieving clinical remission in patients with severe asthma and non-colonized bronchiectasis undergoing type 2-targeted biologic therapies. Methods: A retrospective longitudinal analysis was conducted on 14 patients with severe asthma and non-cystic fibrosis bronchiectasis without microbiological colonization. Clinical remission was assessed at baseline (T0) and after 12 months (T1) of biologic therapy. Clinical remission was defined according to the Severe Asthma Network Italy (SANI) criteria, including the absence of oral corticosteroid use, no asthma-related symptoms, stable lung function, and no exacerbations. Logistic regression was performed to identify predictors of remission. ROC curves were constructed to evaluate the predictive accuracy of lung function parameters, specifically FEV1 and FVC. Results: After 12 months of biologic therapy, 28.6% of patients (n = 4) achieved clinical remission. The mean FEV1 percentage at baseline was significantly higher in the remission group (92.25 \u00b1 15.64%) compared to the non-remission group (65.10 \u00b1 23.36%, p = 0.034). Logistic regression analysis identified baseline FEV1 as a significant predictor of remission (OR = 1.008, p = 0.050). ROC curve analysis revealed that an FEV1 cutoff of 72.5% had a sensitivity of 100% and a specificity of 70% (AUC = 0.900, p = 0.024) for predicting clinical remission. Conclusions: FEV1 is a crucial predictor of clinical remission in patients with severe asthma and non-colonized bronchiectasis treated with type 2-targeted biologic therapies. An FEV1 threshold of 72.5% can guide clinicians in identifying patients most likely to achieve remission. These findings underline the importance of preserving lung function to optimize therapeutic outcomes in this complex population.<\/jats:p>","DOI":"10.3390\/jcm13216309","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T07:53:43Z","timestamp":1729583623000},"page":"6309","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical Remission Predictors in Non-Colonized Bronchiectasis and Severe Asthma with Type 2-Targeted Biologic Therapy: A Retrospective Real-Life Pilot Study"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9920-780X","authenticated-orcid":false,"given":"Vitaliano Nicola","family":"Quaranta","sequence":"first","affiliation":[{"name":"Respiratory Diseases, University of Bari, 70121 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Portacci","sequence":"additional","affiliation":[{"name":"Respiratory Diseases, University of Bari, 70121 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Montagnolo","sequence":"additional","affiliation":[{"name":"Respiratory Diseases, University of Bari, 70121 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1563-6864","authenticated-orcid":false,"given":"Silvano","family":"Dragonieri","sequence":"additional","affiliation":[{"name":"Respiratory Diseases, University of Bari, 70121 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Iorillo","sequence":"additional","affiliation":[{"name":"Respiratory Diseases, University of Bari, 70121 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernesto","family":"Lulaj","sequence":"additional","affiliation":[{"name":"Respiratory Diseases, University of Bari, 70121 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Maselli","sequence":"additional","affiliation":[{"name":"Respiratory Diseases, University of Bari, 70121 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Buonamico","sequence":"additional","affiliation":[{"name":"Respiratory Diseases, University of Bari, 70121 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna Elisiana","family":"Carpagnano","sequence":"additional","affiliation":[{"name":"Respiratory Diseases, University of Bari, 70121 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,22]]},"reference":[{"key":"ref_1","unstructured":"Global Initiative for Asthma (2024, October 21). Global Strategy for Asthma Management and Prevention. 2024. Updated May 2024. Available online: www.ginasthma.org."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jaci.2019.12.006","article-title":"An expert consensus framework for asthma remission as a treatment goal","volume":"145","author":"Bafadhel","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1700629","DOI":"10.1183\/13993003.00629-2017","article-title":"European Respiratory Society guidelines for the management of adult bronchiectasis","volume":"50","author":"Polverino","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"106491","DOI":"10.1016\/j.rmed.2021.106491","article-title":"Mepolizumab effectiveness in patients with severe eosinophilic asthma and co-presence of bronchiectasis: A real-world retrospective pilot study","volume":"185","author":"Crimi","year":"2021","journal-title":"Respir. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1901333","DOI":"10.1183\/13993003.01333-2019","article-title":"Anti-IL5 and anti-IL5R\u03b1 therapy for clinically significant bronchiectasis with eosinophilic endotype: A case series","volume":"55","author":"Rademacher","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S2213-2600(23)00415-0","article-title":"Pioneering a paradigm shift in asthma management: Remission as a treatment goal","volume":"12","author":"Lommatzsch","year":"2024","journal-title":"Lancet Respir. Med."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Campisi, R., Nolasco, S., Pelaia, C., Impellizzeri, P., D\u2019Amato, M., Portacci, A., Ricciardi, L., Scioscia, G., Crimi, N., and Scichilone, N. (2023). Benralizumab Effectiveness in Severe Eosinophilic Asthma with Co-Presence of Bronchiectasis: A Real-World Multicentre Observational Study. J. Clin. Med., 12.","DOI":"10.3390\/jcm12123953"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2147\/JAA.S196200","article-title":"Severe uncontrolled asthma with bronchiectasis: A pilot study of an emerging phenotype that responds to mepolizumab","volume":"12","author":"Carpagnano","year":"2019","journal-title":"J. Asthma Allergy"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur. Respir. J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1016\/j.jaip.2023.07.041","article-title":"Severe Asthma Network Italy Definition of Clinical Remission in Severe Asthma: A Delphi Consensus","volume":"11","author":"Canonica","year":"2023","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.200801-060ST","article-title":"An Official American Thoracic Society\/European Respiratory Society Statement: Asthma Control and Exacerbations","volume":"180","author":"Reddel","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/thx.39.2.81","article-title":"Definitions of emphysema a, chronic bronchitis, asthma, and airflow obstruction: 25 years on from the Ciba symposium","volume":"39","author":"Fletcher","year":"1984","journal-title":"Thorax"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1164\/ajrccm.162.4.9906120","article-title":"An Investigation into Causative Factors in Patients with Bronchiectasis","volume":"162","author":"Pasteur","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S2213-2600(21)00277-0","article-title":"Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: International consensus recommendations","volume":"10","author":"Aliberti","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1164\/rccm.201309-1575OC","article-title":"The Bronchiectasis Severity Index. An International Derivation and Validation Study","volume":"189","author":"Chalmers","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1183\/09031936.00026313","article-title":"Multidimensional approach to BQNFQ the FACED score","volume":"43","author":"Relat","year":"2014","journal-title":"Eur. Respir. J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1148\/radiol.2462070712","article-title":"Fleischner Society: Glossary of terms for thoracic imaging","volume":"246","author":"Hansell","year":"2008","journal-title":"Radiology"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"American Thoracic Society, and European Respiratory Society (2005). ATS\/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide. Am. J. Respir. Crit. Care Med., 171, 912\u2013930.","DOI":"10.1164\/rccm.200406-710ST"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4104\/pcrj.2009.00010","article-title":"The Asthma Control Test (ACT) as a predictor of GINA guideline-defined asthma control: Analysis of a multinational cross-sectional survey","volume":"18","author":"Thomas","year":"2009","journal-title":"Prim. Care Respir. J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1089\/jamp.2015.1212","article-title":"Validation of the \u201cTest of Adherence to Inhalers\u201d (TAI) for Asthma and COPD Patients","volume":"29","author":"Plaza","year":"2016","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1398-9995.2011.02728.x","article-title":"Practical guide to skin prick tests in allergy to aeroallergens","volume":"67","author":"Bousquet","year":"2012","journal-title":"Allergy"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of spirometry, ATS\/ERS Task Force. Practice Guideline","volume":"26","author":"Miller","year":"2005","journal-title":"Eur. Respir. J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12931-021-01729-5","article-title":"Risk factors for Pseudomonas aeruginosa colonization in non-cystic fibrosis bronchiectasis and clinical implications","volume":"22","author":"Kwok","year":"2021","journal-title":"Respir. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12931-024-02812-3","article-title":"Barriers to clinical remission in severe asthma","volume":"25","author":"Farinha","year":"2024","journal-title":"Respir. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.chest.2023.10.046","article-title":"Clinical response and remission in patients with severe asthma treated with biologic therapies","volume":"165","author":"Hansen","year":"2024","journal-title":"Chest"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s12931-023-02539-7","article-title":"Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: Orbe II study","volume":"24","year":"2023","journal-title":"Respir. Res."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Sposato, B., Bianchi, F., Ricci, A., and Scalese, M. (2023). Clinical Asthma Remission Obtained with Biologics in Real Life: Patients\u2019 Prevalence and Characteristics. J. Pers. Med., 13.","DOI":"10.3390\/jpm13061020"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Quarato, C.M.I., Tondo, P., Lacedonia, D., Soccio, P., Fuso, P., Sabato, E., Hoxhallari, A., Foschino Barbaro, M.P., and Scioscia, G. (2024). Clinical Remission in Patients Affected by Severe Eosinophilic Asthma on Dupilumab Therapy: A Long-Term Real-Life Study. J. Clin. Med., 13.","DOI":"10.3390\/jcm13010291"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1007\/s12325-022-02098-1","article-title":"Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab","volume":"39","author":"Hoyte","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2300819","DOI":"10.1183\/13993003.00819-2023","article-title":"Clinical remission in severe asthma with biologic therapy: An analysis from the UK Severe Asthma Registry","volume":"62","author":"McDowell","year":"2023","journal-title":"Eur. Respir. J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1136\/thoraxjnl-2020-215168","article-title":"Characterisation of patients with severe asthma in the UK Severe Asthma Registry in the biologic era","volume":"76","author":"Jackson","year":"2021","journal-title":"Thorax"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1164\/rccm.202108-1889OC","article-title":"Characterization of Eosinophilic Bronchiectasis: A European Multicohort Study","volume":"205","author":"Shoemark","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.anai.2020.11.014","article-title":"Efficacy of type 2-targeted biologics in patients with asthma and bronchiectasis","volume":"126","author":"Kudlaty","year":"2021","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/ACI.0000000000000492","article-title":"Bronchiectasis and asthma: A dangerous liaison?","volume":"19","author":"Crimi","year":"2019","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2101499","DOI":"10.1183\/13993003.01499-2021","article-title":"ERS\/ATS technical standard on interpretive strategies for routine lung function tests","volume":"60","author":"Stanojevic","year":"2022","journal-title":"Eur. Respir. J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1159\/000511459","article-title":"Bronchiectasis in Severe Asthma: Does It Make a Difference?","volume":"99","author":"Bendien","year":"2020","journal-title":"Respiration"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/21\/6309\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:17:52Z","timestamp":1760113072000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/21\/6309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,22]]},"references-count":36,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["jcm13216309"],"URL":"https:\/\/doi.org\/10.3390\/jcm13216309","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,22]]}}}